Cargando…

Airway Findings in Patients with Hunter Syndrome Treated with Intravenous Idursulfase

People with Hunter syndrome are known to be affected by a variety of airway pathologies. Treatment of Hunter syndrome with the enzyme replacement therapy (ERT) idursulfase is now the standard of care. However, it is not known how ERT changes the progression of airway involvement. To evaluate this, w...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Vuyst, Richard, Jalazo, Elizabeth, Tsujimoto, Tamy Moraes, Lin, Feng-Chang, Muenzer, Joseph, Muhlebach, Marianne S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863383/ https://www.ncbi.nlm.nih.gov/pubmed/36675409 http://dx.doi.org/10.3390/jcm12020480

Ejemplares similares

Toileting Abilities Survey as a surrogate outcome measure for cognitive function: Findings from neuronopathic mucopolysaccharidosis II patients treated with idursulfase and intrathecal idursulfase
por: Hogan, Melissa J., et al.
Publicado: (2020)

Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)
por: Muenzer, Joseph, et al.
Publicado: (2017)

Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS)
por: Muenzer, Joseph, et al.
Publicado: (2021)

Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future
por: Whiteman, David AH, et al.
Publicado: (2017)

Comparative study of idursulfase beta and idursulfase in vitro and in vivo
por: Kim, Chihwa, et al.
Publicado: (2017)

Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter Syndrome)
por: Sohn, Young Bae, et al.
Publicado: (2013)

Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome)
por: Pano, Arian, et al.
Publicado: (2015)

Biodistribution of Idursulfase Formulated for Intrathecal Use (Idursulfase-IT) in Cynomolgus Monkeys after Intrathecal Lumbar Administration
por: Chung, Jou-Ku, et al.
Publicado: (2016)

Response to: Investigating the neurobehavioral symptoms of neuronopathic Hunter syndrome
por: Eisengart, J.B., et al.
Publicado: (2020)

Pharmacokinetics and Bioavailability of a Therapeutic Enzyme (Idursulfase) in Cynomolgus Monkeys after Intrathecal and Intravenous Administration
por: Xie, Hongsheng, et al.
Publicado: (2015)

The nature and impact of neurobehavioral symptoms in neuronopathic Hunter syndrome
por: Eisengart, J.B., et al.
Publicado: (2019)

Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients
por: Giugliani, R., et al.
Publicado: (2017)

Review of the use of idursulfase in the treatment of mucopolysaccharidosis II
por: Burrow, T Andrew, et al.
Publicado: (2008)

A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4–7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy
por: Giugliani, Roberto, et al.
Publicado: (2014)

Management of a difficult airway in Hunters syndrome
por: Jain, Aditi, et al.
Publicado: (2022)

Hunter's syndrome and the airway: Implications for the anesthesiologist - A correspondence
por: Chatterjee, Nilay, et al.
Publicado: (2017)

The Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS) Questionnaire: item reduction and further validation
por: Wiklund, Ingela, et al.
Publicado: (2014)

The role of enzyme replacement therapy in severe Hunter syndrome—an expert panel consensus
por: Muenzer, Joseph, et al.
Publicado: (2011)

Metabonomics reveals altered metabolites related to inflammation and energy utilization at recovery of cystic fibrosis lung exacerbation
por: Muhlebach, Marianne S., et al.
Publicado: (2019)

Case report of treatment experience with idursulfase beta (Hunterase) in an adolescent patient with MPS II
por: Ngu, Lock-Hock, et al.
Publicado: (2017)

Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS)
por: Spataro, Federico, et al.
Publicado: (2022)

A new strategy of desensitization in mucopolysaccharidosis type II disease treated with idursulfase therapy: A case report and review of the literature
por: Gragnaniello, Vincenza, et al.
Publicado: (2022)

Levels of glycosaminoglycans in the cerebrospinal fluid of healthy young adults, surrogate-normal children, and Hunter syndrome patients with and without cognitive impairment
por: Hendriksz, Christian J., et al.
Publicado: (2015)

Bow hunter syndrome
por: Kühn, Anna Luisa, et al.
Publicado: (2022)

Perioperative airway management for aortic valve replacement in an adult with mucopolysaccharidosis type II (Hunter syndrome)
por: Suzuki, Kazuchika, et al.
Publicado: (2018)

Hunter Syndrome with Extensive Mongolian Spots
por: You, Hyang-Suk, et al.
Publicado: (2017)

Impact of the COVID-19 pandemic on the standard of care for patients with lysosomal storage diseases: A survey of healthcare professionals in the Fabry, Gaucher, and Hunter Outcome Survey registries
por: Elstein, Deborah, et al.
Publicado: (2021)

Hunter Syndrome Diagnosed by Otorhinolaryngologist
por: Hashimoto, Ayako, et al.
Publicado: (2018)

The Effect of Recombinant Human Iduronate-2-Sulfatase (Idursulfase) on Growth in Young Patients with Mucopolysaccharidosis Type II
por: Żuber, Zbigniew, et al.
Publicado: (2014)

A review of the clinical outcomes in idursulfase-treated and untreated Filipino patients with mucopolysaccharidosis type II: data from the local lysosomal storage disease registry
por: Racoma, Marie Julianne C., et al.
Publicado: (2021)

CNS Penetration of Intrathecal-Lumbar Idursulfase in the Monkey, Dog and Mouse: Implications for Neurological Outcomes of Lysosomal Storage Disorder
por: Calias, Pericles, et al.
Publicado: (2012)

Long-term experience with idursulfase beta (Hunterase) in two adolescent patients with MPS II: A case series
por: Chan, Mei-Yan, et al.
Publicado: (2023)

Bow hunter’s syndrome treated by anterior decompression with fusion: A case report
por: Morita, Kazuya, et al.
Publicado: (2022)

Growth charts for patients with Hunter syndrome()
por: Patel, Pravin, et al.
Publicado: (2014)

Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey
por: Link, Bianca, et al.
Publicado: (2010)

A De Novo Cause of PGM3 Deficiency Treated with Hematopoietic Stem Cell Transplantation
por: Winslow, Andrew, et al.
Publicado: (2022)

Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry
por: Muenzer, Joseph, et al.
Publicado: (2017)

Anesthetic management of a child with Hunter's syndrome
por: Kaur, Jasmeet, et al.
Publicado: (2012)

A rare case of mucopolysaccharidosis: Hunter syndrome
por: Gajula, Prathima, et al.
Publicado: (2012)

Pebbling of skin: Cutaneous marker of Hunter syndrome
por: Srinivas, Sahana M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_k9nmj2kcd4hcs6a6qu48bt3ldk